United Therapeutics (UTHR) CEO Rothblatt Sells $5.2M of Stock

United Therapeutics Corporation Chairperson and CEO Martine A Rothblatt sold 9,500 shares of stock on October 19, 2026, according to a Form 4 filing with the SEC. The shares were sold at an average price of $543.32, for a total value of about $5.2 million.

UTHR United Therapeutics Corporation

$547.21 ▲ +10.16% year to date

1M 3M YTD

Daily close · Oct 20, 2026

Inside Martine A Rothblatt's United Therapeutics Trade

The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Following the sale, Rothblatt directly held 324,443 shares of the drug maker, marking a 2.8% reduction in her personal holdings. This follows a string of similar planned stock sales by the chief executive officer earlier in October. The stock closed at $543.15 on the day of the trade.

Other Institutional Activity in United Therapeutics

Institutional investors have been actively shifting their positions in the biotech firm. Avoro Capital Advisors LLC grew its holdings by 147,804 shares, ending with 2,777,777 shares worth about $1.5 billion. Renaissance Technologies, LLC reduced its stake by selling 78,271 shares, leaving it with 1,708,739 shares valued at about $946.4 million. Jupiter Topco LLC increased its position by 100% after adding 415,564 shares, bringing its total to 831,129 shares worth about $460.3 million.

United Therapeutics Corporation Stock Up 3.9%

Shares recently traded around $543.15 as of October 20, 2026, sitting about 10.9% below their 52-week high of $609.35 and well above their 52-week low of $409.07. The company holds a market capitalization of $23.3 billion and trades above both its 50-day moving average of $514.75 and its 200-day moving average of $527.28.

Recent Earnings

For the trailing twelve months, the company reported $3.15 billion in revenue and earnings of $27.89 per share. It posts a net profit margin of 41.6% and a return on equity of 19.3%. The next corporate earnings release is scheduled for October 28, 2026.

Insider Buying and Selling at United Therapeutics Corporation

Executive insiders executed multiple planned sales during October 2026. Prior to this transaction, CEO Martine A Rothblatt sold 9,500 shares on October 16, 9,500 shares on October 15, and another 9,500 shares on October 12. Additionally, General Counsel Paul A. Mahon sold 8,300 shares on October 15.

Analysts Set New Price Targets

Wall Street firms have updated their outlooks on the stock ahead of the upcoming earnings report. On October 19, 2026, Leerink Partners maintained an Outperform rating with a $725.00 price target. Other recent views include an Outperform rating and $708.00 target from RBC Capital on October 8, a maintained Equal-Weight rating with a $566.00 target from Morgan Stanley on October 7, and a Buy rating with a $728.00 target from BTIG on October 1. The stock carries a consensus buy rating across 14 analyst opinions, with a mean price target of $656.93.

About United Therapeutics

United Therapeutics Corporation is a healthcare company based in Silver Spring, Maryland. It focuses on developing and commercializing specialty treatments for patients suffering from severe and chronic medical conditions.

Bottom Line

Investors will look toward the company's earnings report on October 28, 2026, for updated financial guidance. Insider trading activity will continue to be monitored through regulatory disclosures.